Bruce Caswell Acquires 3,175 Shares of Maximus (NYSE:MMS) Stock

February 12, 2026 by InsiderTrades.com

Key Points

CEO Bruce Caswell purchased 3,175 shares on Feb. 10 at $78.45 each (a $249,078.75 purchase), increasing his direct holdings to 328,013 shares; the transaction was disclosed in an SEC filing.
Maximus reported Q4 EPS of $1.85, beating estimates by $0.01 while revenue fell 4.1% year-over-year to $1.35 billion, and the company provided FY 2026 EPS guidance of 8.050–8.350 versus a sell-side consensus of 6.15 for the current fiscal year.
The board raised the quarterly dividend to $0.33 (from $0.30) with an ex-dividend date of Feb. 13 and a 1.7% yield, while the stock has recently traded down (~4.4%) amid heavy institutional ownership and notable stake increases by firms like Norges Bank and Goldman Sachs.

Maximus, Inc. (NYSE:MMS - Get Free Report) CEO Bruce Caswell acquired 3,175 shares of the firm's stock in a transaction on Tuesday, February 10th. The shares were bought at an average cost of $78.45 per share, for a total transaction of $249,078.75. Following the completion of the acquisition, the chief executive officer directly owned 328,013 shares of the company's stock, valued at approximately $25,732,619.85. This represents a 0.98% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Maximus Trading Down 4.4%

Shares of MMS opened at $75.68 on Thursday. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.88. The stock has a market cap of $4.13 billion, a PE ratio of 11.52 and a beta of 0.57. Maximus, Inc. has a 1 year low of $63.77 and a 1 year high of $100.00. The stock has a 50 day simple moving average of $89.50 and a 200-day simple moving average of $86.55.

Maximus (NYSE:MMS - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, beating analysts' consensus estimates of $1.84 by $0.01. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.37 billion. During the same period in the prior year, the business posted $1.61 earnings per share. The business's revenue was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, sell-side analysts predict that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.33 per share. This is an increase from Maximus's previous quarterly dividend of $0.30. The ex-dividend date is Friday, February 13th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.7%. Maximus's dividend payout ratio is 18.26%.

Hedge Funds Weigh In On Maximus

A number of large investors have recently modified their holdings of MMS. Norges Bank acquired a new stake in shares of Maximus in the fourth quarter valued at approximately $60,393,000. Goldman Sachs Group Inc. boosted its position in Maximus by 218.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 583,627 shares of the health services provider's stock valued at $50,379,000 after buying an additional 400,315 shares during the last quarter. Boston Partners increased its stake in shares of Maximus by 113.6% in the 2nd quarter. Boston Partners now owns 657,247 shares of the health services provider's stock valued at $46,435,000 after buying an additional 349,529 shares during the period. UBS Group AG increased its stake in shares of Maximus by 76.8% in the 4th quarter. UBS Group AG now owns 610,354 shares of the health services provider's stock valued at $52,686,000 after buying an additional 265,095 shares during the period. Finally, River Road Asset Management LLC bought a new stake in shares of Maximus during the second quarter worth $18,073,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on MMS shares. Zacks Research raised shares of Maximus from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, December 30th. Weiss Ratings reissued a "buy (b-)" rating on shares of Maximus in a report on Monday, December 29th. Finally, Wall Street Zen lowered Maximus from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy".

Check Out Our Latest Stock Report on MMS

About Maximus

(Get Free Report)

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children's Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.